» Articles » PMID: 28267439

Mechanisms of Colitis-accelerated Colon Carcinogenesis and Its Prevention with the Combination of Aspirin and Curcumin: Transcriptomic Analysis Using RNA-seq

Overview
Date 2017 Mar 8
PMID 28267439
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) remains the leading cause of cancer-related death in the world. Aspirin (ASA) and curcumin (CUR) are widely investigated chemopreventive candidates for CRC. However, the precise mechanisms of their action and their combinatorial effects have not been evaluated. The purpose of the present study was to determine the effect of ASA, CUR, and their combination in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colitis-accelerated colorectal cancer (CAC). We also aimed to characterize the differential gene expression profiles in AOM/DSS-induced tumors as well as in tumors modulated by ASA and CUR using RNA-seq. Diets supplemented with 0.02% ASA, 2% CUR or 0.01% ASA+1% CUR were given to mice from 1week prior to the AOM injection until the experiment was terminated 22weeks after AOM initiation. Our results showed that CUR had a superior inhibitory effect in colon tumorigenesis compared to that of ASA. The combination of ASA and CUR at a lower dose exhibited similar efficacy to that of a higher dose of CUR at 2%. RNA isolated from colonic tissue from the control group and from tumor samples from the experimental groups was subjected to RNA-seq. Transcriptomic analysis suggested that the low-dose combination of ASA and CUR modulated larger gene sets than the single treatment. These differentially expressed genes were situated in several canonical pathways important in the inflammatory network and liver metastasis in CAC. We identified a small subset of genes as potential molecular targets involved in the preventive action of the combination of ASA and CUR. Taken together, the current results provide the first evidence in support of the chemopreventive effect of a low-dose combination of ASA and CUR in CAC. Moreover, the transcriptional profile obtained in our study may provide a framework for identifying the mechanisms underlying the carcinogenesis process from normal colonic tissue to tumor development as well as the cancer inhibitory effects and potential molecular targets of ASA and CUR.

Citing Articles

Synergistic Anti-Cancer Effects of Curcumin and Thymoquinone Against Melanoma.

Mohd H, Michniak-Kohn B Antioxidants (Basel). 2025; 13(12.

PMID: 39765900 PMC: 11672881. DOI: 10.3390/antiox13121573.


Studies on the mechanism of local and extra-intestinal tissue manifestations in AOM-DSS-induced carcinogenesis in BALB/c mice: role of PARP-1, NLRP3, and autophagy.

Singla S, Jena G Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):4321-4337.

PMID: 38091080 DOI: 10.1007/s00210-023-02878-8.


Therapeutic effects of natural polyphenols on colorectal adenomas: Focus on preclinical studies (Review).

Ma F, Lin Y, Ni Z, Chen T, Wang X Oncol Rep. 2023; 49(6).

PMID: 37083076 PMC: 10170480. DOI: 10.3892/or.2023.8549.


Identification of Novel Core Genes Involved in Malignant Transformation of Inflamed Colon Tissue Using a Computational Biology Approach and Verification in Murine Models.

Markov A, Savin I, Zenkova M, Senkova A Int J Mol Sci. 2023; 24(5).

PMID: 36901742 PMC: 10001800. DOI: 10.3390/ijms24054311.


PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid.

Wang L, Wang C, Sarwar M, Chou P, Wang Y, Su X FASEB J. 2022; 36(11):e22626.

PMID: 36305462 PMC: 9703918. DOI: 10.1096/fj.202201195R.


References
1.
Barrett C, Ning W, Chen X, Smith J, Washington M, Hill K . Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res. 2012; 73(3):1245-55. PMC: 3563732. DOI: 10.1158/0008-5472.CAN-12-3150. View

2.
Jung C, Kim R, Zhang H, Lee S, Sheng H, Loehrer P . HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer. 2005; 92(12):2233-9. PMC: 2361828. DOI: 10.1038/sj.bjc.6602631. View

3.
Wang D, DuBois R, Richmond A . The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol. 2009; 9(6):688-96. PMC: 2787713. DOI: 10.1016/j.coph.2009.08.003. View

4.
Chang L, Lin Y, Mahalingam J, Huang C, Chen T, Kang C . Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012; 72(5):1092-102. DOI: 10.1158/0008-5472.CAN-11-2493. View

5.
Yang Z, Chen H, Huo L, Yang Z, Bai Y, Fan X . Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer. Mol Cancer Res. 2014; 13(1):107-19. DOI: 10.1158/1541-7786.MCR-13-0247. View